(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Researchers identified several antibodies to the nucleocapsid protein from a convalescent COVID-19 patient. Tests found some can inhibit complement hyperactivation and could potentially lead to new ...
Complement is an ancient defense mechanism that evolved into a large protein-interaction network in mammals that initiates and serves innate immune functions and links innate immunity with adaptive ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Investing.com -- Q32 Bio Inc (NASDAQ:QTTB) stock surged 94% in premarket trading Monday after the clinical-stage biotechnology company announced the sale of its Phase 2 complement inhibitor, ADX-097, ...
Q32 Bio Inc (NASDAQ:QTTB) saw its stock skyrocket 94% in premarket trading on Monday after revealing that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics (NASDAQ:AKBA).
Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...
Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors. Complement activation is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback